Skip to main content
. 2022 Apr 20;13:849364. doi: 10.3389/fphar.2022.849364

TABLE 3.

Anti-proliferative activities of compounds 3a-3s against different cell lines.

Compound no. IC50(μM)
KYSE70 KYSE410 KYSE450 H1650 HCC827 SHEE
3a 5.85 ± 0.28 9.70 ± 0.75 5.27 ± 0.31 33.96 ± 2.77 >50 >50
3b 9.03 ± 0.82 17.55 ± 1.37 20.57 ± 1.87 >50 >50 8.05 ± 0.71
3c 5.35 ± 0.34 >50 5.47 ± 0.29 5.72 ± 0.33 >50 22.35 ± 2.53
3d 5.43 ± 0.21 6.91 ± 0.40 4.23 ± 0.19 2.99 ± 0.13 8.17 ± 0.42 >50
3e 12.60 ± 1.01 >50 6.25 ± 0.35 21.10 ± 1.74 >50 >50
3f >50 >50 34.20 ± 3.01 >50 17.81 ± 1.61 12.14 ± 1.33
3g 5.46 ± 0.23 >50 44.46 ± 4.23 29.58 ± 2.18 >50 8.01 ± 0.83
3h >50 >50 >50 >50 >50 6.03 ± 0.57
3i 36.08 ± 3.17 >50 >50 >50 24.23 ± 2.34 6.23 ± 0.62
3j 3.72 ± 0.33 >50 3.60 ± 0.27 4.98 ± 0.17 6.27 ± 0.42 7.2 ± 0.63
3k 16.0 ± 1.53 32.00 ± 3.25 20.00 ± 2.25 16.02 ± 1.69 6.18 ± 0.61 10.33 ± 0.96
3l 11.11 ± 0.94 >50 >50 10.02 ± 0.79 4.61 ± 0.28 4.82 ± 0.32
3m 3.92 ± 0.15 5.85 ± 0.20 4.05 ± 0.21 4.27 ± 0.19 8.44 ± 0.37 >50
3n >50 49.70 ± 4.57 12.76 ± 1.25 35.35 ± 3.46 13.71 ± 1.34 22.59 ± 2.31
3o >50 49.5 ± 5.01 46.76 ± 4.63 >50 >50 14.17 ± 1.61
3p >50 >50 24.90 ± 2.16 >50 34.67 >50
3q >50 12.27 ± 0.93 >50 >50 >50 28.08 ± 2.47
3r 5.85 ± 0.52 8.74 ± 0.74 8.20 ± 0.67 4.32 ± 0.27 12.43 ± 1.07 >50
3s >50 >50 >50 >50 >50 33.26 ± 3.43
Erlotinib >50 5.00 ± 0.46 7.60 ± 0.51 14.00 ± 1.19 11.81 ± 1.02 20.99 ± 2.11

Conditions: Growth inhibition was evaluated with MTT assay. The absorbance at 490 nm was measured using a microplate reader (Thermo). The results were from statistical analysis and were presented as mean ± SD.